MarketCap
Facebook
X
Telegram
Immunovant EV/EBITDA Ratio | IMVT
Annual EV/EBITDA Ratio Immunovant
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.9 K | 4.28 K | 15.1 K | 13.4 K | 17.1 K | 1.7 K | -10.6 | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 17.1 K | -10.6 | 9.36 K |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Annexon
ANNX
|
-3.14 | $ 4.2 | -0.71 % | $ 651 M |  USA |
 |
AbbVie
ABBV
|
24.9 | $ 293.87 | 0.19 % | $ 520 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
77.8 | $ 151.6 | -3.2 % | $ 19.9 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-41 | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
0.57 | - | -52.27 % | $ 4.45 M | USA |
 |
Axon Enterprise
AXON
|
1.57 K | $ 302.6 | -0.19 % | $ 23.6 B | USA |
 |
Theratechnologies
THTX
|
17 | - | - | $ 83.9 M |  Canada |
 |
Liquidia Corporation
LQDA
|
-61 | $ 51.37 | 7.31 % | $ 4.42 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-6.79 | $ 45.05 | -9.97 % | $ 4.05 B |  Schweiz |
 |
Scholar Rock Holding Corporation
SRRK
|
-12.8 | $ 48.48 | -5.96 % | $ 5.56 B | USA |
 |
Geron Corporation
GERN
|
-19.5 | $ 0.96 | -3.71 % | $ 640 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
45.8 | $ 62.8 | 1.06 % | $ 128 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
0.516 | - | -3.76 % | $ 3.47 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-1.24 | $ 7.4 | -0.13 % | $ 113 M |  Australia |
 |
Celldex Therapeutics
CLDX
|
-7.28 | $ 30.68 | -1.81 % | $ 2.04 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-0.355 | $ 4.0 | -6.76 % | $ 48.8 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
-1.22 | - | 3.16 % | $ 1.9 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
31.2 | $ 317.26 | 0.99 % | $ 6.14 B | USA |
 |
Eli Lilly and Company
LLY
|
467 | $ 1 432.7 | 1.47 % | $ 1.29 T | USA |
 |
TCR2 Therapeutics
TCRR
|
-0.615 | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-8.07 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
TFF Pharmaceuticals
TFFP
|
-0.366 | - | -60.05 % | $ 125 K | USA |
 |
Mesoblast Limited
MESO
|
-19.7 | $ 14.0 | -3.06 % | $ 16.9 B | Australia |
 |
CorMedix
CRMD
|
1.83 | $ 5.37 | -2.1 % | $ 387 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-2.47 | - | -15.15 % | $ 60.3 M |  Britain |
 |
MannKind Corporation
MNKD
|
34.4 | $ 4.22 | 0.84 % | $ 1.29 B | USA |
 |
AVEO Pharmaceuticals
AVEO
|
-18.2 | - | - | $ 521 M | USA |
 |
MediciNova
MNOV
|
-3.2 | $ 1.4 | -4.76 % | $ 68.7 M | USA |
 |
Merck & Co.
MRK
|
97.3 | $ 147.75 | -0.68 % | $ 370 B | USA |
 |
Moderna
MRNA
|
-7.16 | $ 250.79 | -6.77 % | $ 97.6 B | USA |
 |
Axcella Health
AXLA
|
-0.295 | - | -16.42 % | $ 249 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
4.01 K | - | - | $ 2.02 B | USA |
 |
Intellia Therapeutics
NTLA
|
-1.83 | $ 11.18 | -7.72 % | $ 1.21 B | USA |
 |
Novartis AG
NVS
|
20.9 | $ 163.39 | -0.18 % | $ 317 B | Schweiz |
 |
Omeros Corporation
OMER
|
-5.43 | $ 17.3 | -1.48 % | $ 1.1 B | USA |
 |
Oramed Pharmaceuticals
ORMP
|
-6.11 | $ 3.97 | -0.75 % | $ 164 M | Israel |
 |
Tyme Technologies
TYME
|
0.228 | - | 8.07 % | $ 54 M | USA |
 |
Puma Biotechnology
PBYI
|
9.01 | $ 8.13 | -3.22 % | $ 407 M | USA |
 |
PDS Biotechnology Corporation
PDSB
|
-0.621 | $ 1.02 | -5.09 % | $ 47.3 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
-3.16 | $ 34.99 | 3.77 % | $ 147 M | USA |
 |
Pfizer
PFE
|
41.7 | $ 29.34 | 0.36 % | $ 167 B | USA |
 |
Завод ДИОД
DIOD
|
7.12 | - | - | - |  Russia |
 |
PainReform Ltd.
PRFX
|
-0.255 | $ 0.78 | -4.24 % | $ 505 K | Israel |
 |
Prothena Corporation plc
PRTA
|
0.0485 | $ 8.56 | -2.51 % | $ 461 M | USA |
 |
Arcus Biosciences
RCUS
|
-5.18 | $ 18.66 | -1.56 % | $ 2 B | USA |
 |
Orgenesis
ORGS
|
-1.03 | - | -33.86 % | $ 61.2 M | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
2.14 | $ 14.9 | -1.03 % | $ 12.4 B |  India |
 |
Regeneron Pharmaceuticals
REGN
|
21.2 | $ 916.16 | -0.41 % | $ 95.8 B | USA |
 |
Replimune Group
REPL
|
-3.15 | $ 23.3 | 4.67 % | $ 2.16 B | USA |
 |
Фармсинтез
LIFE
|
-115 | - | - | - | Russia |